JULIA, YOUR mRNA THERAPEUTICS COPILOT
Experience how Julia orchestrates agentic mRNA construct design, in-vitro validation planning, and manufacturing handoff from a single tumor transcriptomic data
| Patient ID | Tumor Features | Candidate Targets | mRNA Construct | Design Score | Manufacturability | Validation Plan |
|---|---|---|---|---|---|---|
| P-001 | BRCA1-mut, TP53-LOF | KRAS, VEGFR2 | mRNA-4821-v3 | 0.91 | High | Prolif + Casp-3 |
| P-002 | BRCA2-wt, PIK3CA-mut | HER2, mTOR | mRNA-5033-v1 | 0.87 | Medium | Apoptosis + PARP |
Julia
mRNA Design Assistant
Tumor profile for P-001 ingested. BRCA1 mutation detected with TP53 loss-of-function. I've identified KRAS and VEGFR2 as candidate targets. Ready to generate mRNA construct candidates. Shall I proceed?
Yes, design constructs with GC content constraints and check for off-target risks.
Generated 3 construct candidates. Top candidate mRNA-4821-v3 has a design score of 0.91, GC content 48.2%, no off-target flags, and high manufacturability. Predicted expression is strong based on codon optimization. Want to see the validation plan?
Yes, and flag any immunogenicity risks.
Validation plan for mRNA-4821-v3: proliferation assay at 48h and 72h, Caspase-3/7 activation readout, PARP cleavage western blot. No immunogenicity risk flags detected for this sequence. One minor motif advisory on the 5' UTR — documented in the design rationale. Ready for manufacturing handoff package?
Generate the manufacturing handoff with QC checklist.
Manufacturing package ready: sequence file, codon optimization report, QC checklist (purity ≥95%, endotoxin <0.5 EU/mL, cap efficiency ≥90%), and full design rationale with version history. All traceable to the original tumor profile. Export now?
Features
An Agentic Stack for Rapid mRNA Therapeutics Development
From tumor profiling to manufacturing handoff — AI agents orchestrate every step of the mRNA design pipeline
Agent
Agent
Agent
Design
Validation
Handoff
Julia's Agentic Network
Orchestrated by Julia, specialized agents collaborate to profile tumors, design optimized mRNA constructs, plan in-vitro validation assays, and generate ready-to-manufacture packages with full traceability.
Tumor Profiling Ingest
Upload omics and pathology summaries; standardize into a design-ready tumor profile for downstream construct generation
Agentic Target & Construct Design
Multi-agent reasoning and generative sequence design with constraints for GC content, motifs, off-target screening, and manufacturability
In-Vitro Validation Workflows
Built-in experimental plans for proliferation, apoptosis assays, and protein marker readouts tailored to each construct
Manufacturing Handoff
Export ready-to-manufacture packages including sequence files, specifications, and QC checklists for CDMO partners
Safety & Risk Flags
Screen for sequence liabilities, off-target effects, and immunogenicity heuristics with clearly documented risk advisories
Auditability
Full versioning, traceability, and design rationale per construct — from tumor profile to final sequence
Use Cases
Who Julia Is Built For
Accelerating mRNA therapeutics development from bench to manufacturing
Drug-Resistant Ovarian Cancer
Rapid iteration on personalized mRNA constructs for resistant phenotypes, compressing the design-to-validation cycle
Translational Research Teams
Standardize mRNA design and validation workflows across cell lines and patient-derived models with reproducible pipelines
Biotech / CDMO Collaboration
Clean handoff from design to synthesis and manufacture with traceable specs, QC checklists, and version-controlled packages
FAQ
Common Questions
Design-ready mRNA construct candidates, complete with validation plans (proliferation, apoptosis, protein marker assays) and manufacturing handoff packages including sequence files, QC checklists, and full design rationale.
A tumor profile (omics data if available), target hypotheses, and design constraints such as GC content ranges, off-target exclusion lists, or manufacturability preferences. Julia can work with partial inputs and iteratively refine designs.
No. Spheroid AI is positioned as an R&D and therapeutics development platform. It is designed to accelerate the mRNA design-to-manufacture pipeline, not to provide clinical treatment recommendations or medical advice.
Julia generates in-vitro assay plans tailored to each construct: proliferation assays, apoptosis readouts, and apoptotic protein markers (caspases, PARP, BCL2 family as available). All validation steps are documented and traceable.
Pilot with 1–2 models (cell lines or patient-derived samples) and a small design set. Expand iteratively as you validate results and refine constraints. Our team can help scope the initial project.
For research use and development purposes only. Not intended as medical advice.